These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 24293233)
1. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology). Soffietti R; Trevisan E; Bertero L; Cassoni P; Morra I; Fabrini MG; Pasqualetti F; Lolli I; Castiglione A; Ciccone G; Rudà R J Neurooncol; 2014 Feb; 116(3):533-41. PubMed ID: 24293233 [TBL] [Abstract][Full Text] [Related]
2. Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study. Lombardi G; Bellu L; Pambuku A; Della Puppa A; Fiduccia P; Farina M; D'Avella D; Zagonel V J Neurooncol; 2016 Jul; 128(3):481-6. PubMed ID: 27165580 [TBL] [Abstract][Full Text] [Related]
3. AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. Brandes AA; Finocchiaro G; Zagonel V; Reni M; Caserta C; Fabi A; Clavarezza M; Maiello E; Eoli M; Lombardi G; Monteforte M; Proietti E; Agati R; Eusebi V; Franceschi E Neuro Oncol; 2016 Sep; 18(9):1304-12. PubMed ID: 26951379 [TBL] [Abstract][Full Text] [Related]
4. Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology. Pasqualetti F; Pace A; Gonnelli A; Villani V; Cantarella M; Delishaj D; Vivaldi C; Molinari A; Montrone S; Pellerino A; Franchino F; Baldaccini D; Lombardi G; Lolli I; Catania F; Bazzoli E; Morganti R; Fabi A; Zagonel V; Bocci G; Fabrini MG; Rudà R; Soffietti R; Paiar F Am J Clin Oncol; 2018 Dec; 41(12):1272-1275. PubMed ID: 29782366 [TBL] [Abstract][Full Text] [Related]
5. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Brandes AA; Tosoni A; Franceschi E; Blatt V; Santoro A; Faedi M; Amistà P; Gardiman M; Labianca R; Bianchini C; Ermani M; Reni M Cancer Chemother Pharmacol; 2009 Sep; 64(4):769-75. PubMed ID: 19169684 [TBL] [Abstract][Full Text] [Related]
6. Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. Scoccianti S; Detti B; Sardaro A; Iannalfi A; Meattini I; Leonulli BG; Borghesi S; Martinelli F; Bordi L; Ammannati F; Biti G Anticancer Drugs; 2008 Jul; 19(6):613-20. PubMed ID: 18525321 [TBL] [Abstract][Full Text] [Related]
7. Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study. Fabi A; Metro G; Vidiri A; Lanzetta G; Carosi M; Telera S; Maschio M; Russillo M; Sperduti I; Carapella CM; Cognetti F; Pace A J Neurooncol; 2010 Nov; 100(2):209-15. PubMed ID: 20352471 [TBL] [Abstract][Full Text] [Related]
8. A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma. Fabrini MG; Silvano G; Lolli I; Perrone F; Marsella A; Scotti V; Cionini L J Neurooncol; 2009 Mar; 92(1):79-86. PubMed ID: 19018476 [TBL] [Abstract][Full Text] [Related]
10. An overview of fotemustine in high-grade gliomas: from single agent to association with bevacizumab. Lombardi G; Farina P; Della Puppa A; Cecchin D; Pambuku A; Bellu L; Zagonel V Biomed Res Int; 2014; 2014():698542. PubMed ID: 24800248 [TBL] [Abstract][Full Text] [Related]
11. Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation. Kim SH; Yoo H; Chang JH; Kim CY; Chung DS; Kim SH; Park SH; Lee YS; Yang SH J Korean Med Sci; 2018 Jun; 33(24):e167. PubMed ID: 29892208 [TBL] [Abstract][Full Text] [Related]
12. GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status. Pérez-Segura P; Manneh R; Ceballos I; García A; Benavides M; Fuster J; Vaz MA; Cano JM; Berros JP; Covela M; Moreno V; Quintanar T; García Bueno JM; Fernández I; Sepúlveda J Clin Transl Oncol; 2016 Aug; 18(8):805-12. PubMed ID: 26542177 [TBL] [Abstract][Full Text] [Related]